Ortega Morán, L. http://orcid.org/0000-0003-0456-7322
García Alfonso, P.
Aguilar Caballero, I.
Morón García, B.
Tirado Anula, V.
de Toro Carmena, M.
Soto Alsar, J.
Gutiérrez Alonso, N.
Bringas Beranek, M.
Martín Jiménez, M.
Muñoz Martín, A. J. http://orcid.org/0000-0001-6977-8249
Article History
Received: 6 March 2020
Accepted: 16 March 2020
First Online: 8 April 2020
Compliance with ethical standards
:
: Laura Ortega Morán received speakers’ honoraria or honoraria for participation in Advisory Boards from Amgen and Sanofi; travel, accommodations and expenses from Amgen, Leo Pharma, Roche and Sanofi. Pilar García Alfonso received speakers’ honoraria or honoraria for participation in Advisory Boards from Roche, Amgen, Merck, Sanofi and Servier; travel, accommodations and expenses from Roche and Merck. Iker Aguilar Caballero received speakers’ honoraria from Kyowa Kirin; travel, accommodations and expenses from Astra-Zeneca, Roche, and Sanofi. Blanca Morón García received support for travel, accommodations, and expenses from MSD. Victoria Tirado Anula received support for travel, accommodations, and expenses from MSD. María de Toro Carmena received support for travel, accommodations, and expenses from Leo Pharma and MSD. Javier Soto Alsar has an immediate family member employed by Pfizer and Sanofi; travel, accommodations, and expenses from Angelini, MSD, Rovi, Sanofi, and Vifor Pharma. Marianela Bringas Beranek received support for travel, accommodations, and expenses from MSD, Rovi, Sanofi, and Vifor Pharma. Natalia Gutiérrez Alonso received support for travel, accommodations, and expenses from Angelini, MSD, Rovi, and Sanofi. Miguel Martín received speakers’ honoraria or honoraria for participation in Advisory Boards from Roche, Novartis, Pfizer, Lilly, Astra-Zeneca, Taiho Pharmaceutical, and PharmaMar; research funding from Novartis and Roche. Andrés J. Muñoz Martín received speakers’ honoraria or honoraria for participation in Advisory Boards from Astra-Zeneca, Bayer Halozyme, Celgene, Daiichi Sankyo Roche, Leo Pharma, Pfizer, Sanofi, Servier, Amgen, Lilly, and Rovi; research funding from Celgene, Leo Pharma, and Sanofi; patents: risk assessment model in venous thromboembolism in cancer patients; travel, accodomodations, and expenses from Amgen, Celgene, Merck Serono, Roche, and Sanofi.
: The study was approved by the Ethics Committee of Hospital General Universitario Gregorio Marañón, Madrid, Spain. The study has been approved by the appropriate institutional and/or national research ethics committee and has been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
: For this type of study formal consent is not required.